RE:RE:RE:RE:On the takeoverHmmm, it seems I was looking at CXR cashflow for 9 months, not 3rd Qtr.
Dug up some more info on AMCo which maybe matches your numbers fdfd?
Strategic Benefits Position Concordia for Future Growth and Value Creation
- Combined company creates global platform to drive continued expansion
- Positions Concordia as a leading, international specialty pharmaceutical company with commercial reach in over 100 countries
- Adds a diversified, attractive portfolio of more than 190 complementary, niche pharmaceutical products with high barriers to entry
- Expected value creation through financial scale and resources
- On a pro forma basis for the full year 2015, AMCo expects to record revenue of US$530 million - $560 million
- AMCo has experienced historical strong financial performance, with 2012-2014 revenue CAGR of 18%, high margins and historical cash flow conversion of approximately 90%3
- On a pro forma basis, the combined company is expected to achieve revenue of US$870 million - $920 million for full year 2015 and adjusted EBITDA4 of US$510 million - $540 million for full year 2015